Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
Journal article published in 2019 by
Owen A. O’Connor,
Lorenzo Falchi 
,
Jennifer K. Lue,
Enrica Marchi,
Cristina Kinahan,
Ahmed Sawas,
Changchun Deng,
Francesca Montanari,
Jennifer E. Amengual,
Hye A. Kim,
Aishling M. Rada,
Karen Khan,
Alice T. Jacob,
Michelle Malanga,
Mark M. Francescone
and other authors.
,
Jennifer K. Lue,
Enrica Marchi,
Cristina Kinahan,
Ahmed Sawas,
Changchun Deng,
Francesca Montanari,
Jennifer E. Amengual,
Hye A. Kim,
Aishling M. Rada,
Karen Khan,
Alice T. Jacob,
Michelle Malanga,
Mark M. Francescone
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
The authors report a phase 1 study of romidepsin combined with oral 5-azacytidine in patients with relapsed/refractory lymphomas, including complete remissions in 3 patients with angioimmunoblastic T-cell lymphoma.